DYRK1A and Alzheimer disease: Finally, normalization of the DYRK1A function in AD and DS could be achieved by developing the approaches for decreasing the protein levels without targeting its catalytic activity, such as use of PROteolysis Targeting Chimeras (PROTACs) (Choudhary et al., 2023; Thomas et al., 2023).